Search Results - "Feelders, Richard Abraham"
-
1
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
Published in The lancet. Diabetes & endocrinology (01-01-2018)“…Cushing's disease is a rare debilitating endocrine disorder for which few prospective interventional studies have been done. We report results of the first…”
Get full text
Journal Article -
2
THU090 18F-FET PET-MRI; A Novel And Improved Technique For Detection Of Small Functional Pituitaryadenomas
Published in Journal of the Endocrine Society (05-10-2023)“…Disclosure: I. Pruis: None. E. verbrug: None. M. smits: None. M. vernooij: None. R.A. Feelders: None. R. Blavers: None. S. velthuijzen: None. S.J. Neggers:…”
Get full text
Journal Article -
3
A Prospective Trial With Ketoconazole Induction Therapy and Octreotide Maintenance Treatment of Cushing’s Disease
Published in Journal of the Endocrine Society (03-05-2021)“…Context: The lack of efficacy of octreotide in the medical treatment of Cushing’s disease (CD) may result from suppressive effects of hypercortisolism on…”
Get full text
Journal Article -
4
THU033 High Prevalence Of Venous Thrombotic Events In Cushing’s Syndrome: Data From ERCUSYN
Published in Journal of the Endocrine Society (05-10-2023)“…Disclosure: K. Isand: None. R.A. Feelders: None. T.C. Brue: None. M. Toth: None. T. Deutschbein: None. M. Reincke: None. M. Krsek: None. A. Santos: None. F…”
Get full text
Journal Article -
5
FRI296 Somatostatin Receptor 5 Staining In Prolactinomas
Published in Journal of the Endocrine Society (05-10-2023)“…Disclosure: S. Mehta: None. R.A. Feelders: Advisory Board Member; Self; Corcept. Research Investigator; Self; Recordati, Strongbridge. L.J. Hofland: None. C…”
Get full text
Journal Article -
6
9323 Open-label Results From Grace, A Phase 3 Double-blind, Randomized-withdrawal Study Of The Selective Glucocorticoid Receptor Modulator Relacorilant For The Treatment Of Endogenous Hypercortisolism (Cushing Syndrome)
Published in Journal of the Endocrine Society (05-10-2024)“…Disclosure: R. Pivonello: Consulting Fee; Self; Corcept Therapeutics, Recordati AG, Crinetics Pharmaceuticals, H. Lundbeck A/S. Other; Self; Corcept- Research…”
Get full text
Journal Article